PubRank

Rameen Beroukhim

Author PubWeight™ 314.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterizing the cancer genome in lung adenocarcinoma. Nature 2007 16.48
2 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005 15.42
3 Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005 15.28
4 High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007 12.68
5 Molecular definition of breast tumor heterogeneity. Cancer Cell 2007 12.67
6 The somatic genomic landscape of glioblastoma. Cell 2013 11.73
7 Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012 10.87
8 GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011 9.60
9 Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004 9.41
10 Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012 7.76
11 Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013 7.73
12 TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006 7.61
13 SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009 7.48
14 Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 2008 7.45
15 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009 7.09
16 Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005 6.93
17 Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011 6.89
18 Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010 6.39
19 Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009 6.35
20 Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010 6.10
21 Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008 5.95
22 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
23 Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009 5.07
24 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006 4.63
25 Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013 4.48
26 Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 2012 4.35
27 Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012 4.13
28 Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009 3.45
29 Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov 2011 3.45
30 Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 2012 3.41
31 Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res 2004 3.37
32 The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011 3.37
33 β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012 3.33
34 Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013 3.19
35 An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010 3.09
36 Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009 3.03
37 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2015 3.00
38 Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012 2.84
39 Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol 2005 2.84
40 Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009 2.77
41 Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2008 2.75
42 Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009 2.73
43 Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009 2.47
44 High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008 2.46
45 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 2.42
46 Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011 2.34
47 Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012 2.26
48 Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009 2.07
49 Cancer vulnerabilities unveiled by genomic loss. Cell 2012 1.95
50 Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012 1.93
51 ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 2012 1.86
52 Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res 2012 1.82
53 Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004 1.82
54 A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A 2010 1.81
55 The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 2013 1.75
56 Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007 1.75
57 Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 2007 1.66
58 BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 2013 1.64
59 Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics 2008 1.62
60 Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012 1.54
61 SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res 2008 1.51
62 ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010 1.33
63 Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013 1.33
64 Medical therapies for meningiomas. J Neurooncol 2010 1.30
65 Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med 2013 1.19
66 Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 2013 1.09
67 A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol 2012 1.07
68 The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods 2010 1.06
69 Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One 2013 1.02
70 Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol 2011 1.02
71 Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 2005 0.99
72 In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A 2014 0.99
73 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013 0.96
74 Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 2014 0.89
75 HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008 0.88
76 Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2011 0.88
77 Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs 2013 0.86
78 Prioritizing causal disease genes using unbiased genomic features. Genome Biol 2014 0.82
79 Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol 2016 0.77
80 Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology 2010 0.77
81 Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol 2015 0.77
82 Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol 2014 0.76
83 Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep 2017 0.75
84 Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep 2016 0.75